Q2 EPS Estimates for Krystal Biotech Decreased by Analyst

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Equities research analysts at William Blair reduced their Q2 2025 earnings per share estimates for shares of Krystal Biotech in a report issued on Wednesday, July 9th. William Blair analyst S. Corwin now expects that the company will earn $1.36 per share for the quarter, down from their previous estimate of $1.47. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech's Q4 2025 earnings at $1.76 EPS, Q1 2026 earnings at $1.42 EPS, Q2 2026 earnings at $1.82 EPS, Q3 2026 earnings at $2.30 EPS and Q4 2026 earnings at $2.65 EPS.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). The firm had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%.

Several other brokerages also recently commented on KRYS. Guggenheim cut their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Chardan Capital restated a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a research note on Wednesday, May 7th. Citigroup restated a "neutral" rating and issued a $176.00 target price (up previously from $155.00) on shares of Krystal Biotech in a research note on Wednesday. Finally, HC Wainwright restated a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a research note on Tuesday, June 24th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Krystal Biotech presently has an average rating of "Buy" and a consensus target price of $213.75.

Krystal Biotech Stock Performance

KRYS stock opened at $149.74 on Friday. The company has a market capitalization of $4.33 billion, a price-to-earnings ratio of 36.00 and a beta of 0.67. Krystal Biotech has a fifty-two week low of $122.80 and a fifty-two week high of $219.34. The stock has a fifty day moving average of $136.18 and a 200-day moving average of $156.34.

Hedge Funds Weigh In On Krystal Biotech

A number of large investors have recently modified their holdings of KRYS. Brooklyn Investment Group raised its holdings in shares of Krystal Biotech by 291.7% during the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock valued at $25,000 after buying an additional 105 shares in the last quarter. Twin Tree Management LP purchased a new position in shares of Krystal Biotech during the 1st quarter valued at about $29,000. Fifth Third Bancorp raised its holdings in shares of Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after buying an additional 105 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Krystal Biotech by 128.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company's stock valued at $58,000 after buying an additional 177 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in Krystal Biotech during the 1st quarter worth approximately $74,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.